News|Articles|June 17, 2025

Myasthenia Gravis Awareness Month 2025: CAR-T Continues Steady Progress

In observance of Myasthenia Gravis Awareness Month, held annually in June, we took a look back at the past year's progress in bringing CAR-T to this autoimmune disease.

Myasthenia gravis (MG) is a rare neuromuscular disorder, characterized by weakening of the skeletal muscles that drive movement, that affects at least 36,000 to 60,000 people in the United States. MG is among the autoimmune diseases that has recently attracted attention for the development of chimeric antigen receptor T-cell (CAR-T) therapy, and several biotech companies are currently working on such products for the indication.